To prove that this did not happen, we tested the binding capacity of chimeric molecules to CD35 expressed on human B and T cells isolated from HT patients against a FITC (flourescein isothiocyanate)-conjugated antibody with the same specificity. The gene discussed is CR1; the disease is hematocrit.